Literature DB >> 8406384

Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype.

P C de Bruin1, R C Beljaards, P van Heerde, P Van Der Valk, L A Noorduyn, J H Van Krieken, J C Kluin-Nelemans, R Willemze, C J Meijer.   

Abstract

The histological, immunophenotypic and clinical features of 19 primary cutaneous anaplastic large cell lymphomas (cutaneous ALCL) were compared with those of 18 primary nodal anaplastic large cell lymphomas (nodal ALCL) of T-cell or null cell type. Although cutaneous ALCL and nodal ALCL had identical morphological features, differences in surface marker expression and clinical behaviour were found. Immunophenotypical differences concerned the expression of epithelial membrane antigen (82% of the nodal ALCL were positive v. none of the cutaneous ALCL) and the cutaneous lymphocyte antigen (HECA-452), a possible skin-homing receptor on cutaneous T-lymphocytes (most tumour cells in 44% of cutaneous ALCL cases were positive, whereas nodal ALCL showed expression of HECA-452 on only few tumour cells (< 25%) in 18% of cases tested). Loss of T-cell markers was more pronounced for nodal ALCL. Patients with cutaneous ALCL were generally older (median 61 years) than patients with nodal ALCL (median 24 years) and, in contrast to the latter group, did not show bimodal age distribution. Survival after 4 years, using lymphoma-related death as an end-point, differed significantly between cutaneous ALCL and nodal ALCL; 92% for cutaneous ALCL and 65% for nodal ALCL (P = 0.04). The better survival of cutaneous ALCL patients could not be ascribed to differences in age, stage or initial mode of treatment. These data indicate that differences in immunophenotype and clinical behaviour exist between morphologically identical primary cutaneous and primary node-based ALCL. They indicate that the primary site is an important prognostic factor in predicting the clinical outcome of ALCL.

Entities:  

Mesh:

Year:  1993        PMID: 8406384     DOI: 10.1111/j.1365-2559.1993.tb00470.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  9 in total

1.  The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements.

Authors:  S Pittaluga; I Wlodarska; K Pulford; E Campo; S W Morris; H Van den Berghe; C De Wolf-Peeters
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

2.  MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form.

Authors:  R L ten Berge; F G Snijdewint; S von Mensdorff-Pouilly; R J Poort-Keesom; J J Oudejans; J W Meijer; R Willemze; J Hilgers; C J Meijer
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

3.  ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination.

Authors:  R L ten Berge; J J Oudejans; G J Ossenkoppele; K Pulford; R Willemze; B Falini; A Chott; C J Meijer
Journal:  J Clin Pathol       Date:  2000-06       Impact factor: 3.411

Review 4.  EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.

Authors:  Werner Kempf; Katrin Pfaltz; Maarten H Vermeer; Antonio Cozzio; Pablo L Ortiz-Romero; Martine Bagot; Elise Olsen; Youn H Kim; Reinhard Dummer; Nicola Pimpinelli; Sean Whittaker; Emmilia Hodak; Lorenzo Cerroni; Emilio Berti; Steve Horwitz; H Miles Prince; Joan Guitart; Teresa Estrach; José A Sanches; Madeleine Duvic; Annamari Ranki; Brigitte Dreno; Sonja Ostheeren-Michaelis; Robert Knobler; Gary Wood; Rein Willemze
Journal:  Blood       Date:  2011-08-12       Impact factor: 22.113

5.  Detection of t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis.

Authors:  M Beylot-Barry; L Lamant; B Vergier; A de Muret; S Fraitag; B Delord; P Dubus; L Vaillant; M Delaunay; G MacGrogan; C Beylot; A de Mascarel; G Delsol; J P Merlio
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

6.  Spectrum of CD30+ lymphoid proliferations in the eyelid lymphomatoid papulosis, cutaneous anaplastic large cell lymphoma, and anaplastic large cell lymphoma.

Authors:  R Krishna Sanka; Ralph C Eagle; Ted H Wojno; Kenneth R Neufeld; Hans E Grossniklaus
Journal:  Ophthalmology       Date:  2009-12-06       Impact factor: 12.079

7.  [Primary cutaneous CD30+ ALK(-) anaplastic large cell T-cell lymphoma].

Authors:  C Mühlhoff; A Rübben; N Gassler; M Megahed
Journal:  Hautarzt       Date:  2009-12       Impact factor: 0.751

8.  Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumab.

Authors:  Chad J Hruska; Robert J Bertoli; Yorke D Young; Patrick H Burkhart; Paul B Googe
Journal:  JAAD Case Rep       Date:  2015-02-05

Review 9.  Anaplastic Large Cell Lymphoma: Molecular Pathogenesis and Treatment.

Authors:  Xin-Rui Zhang; Pham-Ngoc Chien; Sun-Young Nam; Chan-Yeong Heo
Journal:  Cancers (Basel)       Date:  2022-03-24       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.